These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36861804)

  • 21. [The role of pharmacology to produce firuglipel (DS-8500a), an orally available GPR119 agonist for type 2 diabetes mellitus].
    Matsumoto K; Yoshitomi T; Shimada T
    Nihon Yakurigaku Zasshi; 2018; 152(3):119-124. PubMed ID: 30185729
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 2-Oleoyl glycerol is a GPR119 agonist and signals GLP-1 release in humans.
    Hansen KB; Rosenkilde MM; Knop FK; Wellner N; Diep TA; Rehfeld JF; Andersen UB; Holst JJ; Hansen HS
    J Clin Endocrinol Metab; 2011 Sep; 96(9):E1409-17. PubMed ID: 21778222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release.
    Chu ZL; Jones RM; He H; Carroll C; Gutierrez V; Lucman A; Moloney M; Gao H; Mondala H; Bagnol D; Unett D; Liang Y; Demarest K; Semple G; Behan DP; Leonard J
    Endocrinology; 2007 Jun; 148(6):2601-9. PubMed ID: 17289847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GPR119 agonists: a promising new approach for the treatment of type 2 diabetes and related metabolic disorders.
    Shah U
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):519-32. PubMed ID: 19562648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell.
    Lauffer LM; Iakoubov R; Brubaker PL
    Diabetes; 2009 May; 58(5):1058-66. PubMed ID: 19208912
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus : Focus on Bile Acid Sequestrants.
    Holst JJ; McGill MA
    Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 27933595
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease-A Systematic Review.
    Mori Y; Matsui T; Hirano T; Yamagishi SI
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32098413
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incretin hormones: Their role in health and disease.
    Nauck MA; Meier JJ
    Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():5-21. PubMed ID: 29364588
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stimulation of proglucagon gene expression by human GPR119 in enteroendocrine L-cell line GLUTag.
    Chepurny OG; Bertinetti D; Diskar M; Leech CA; Afshari P; Tsalkova T; Cheng X; Schwede F; Genieser HG; Herberg FW; Holz GG
    Mol Endocrinol; 2013 Aug; 27(8):1267-82. PubMed ID: 23798572
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants.
    Holst JJ; McGill MA
    Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 21958333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bidirectional GPR119 Agonism Requires Peptide YY and Glucose for Activity in Mouse and Human Colon Mucosa.
    Tough IR; Forbes S; Herzog H; Jones RM; Schwartz TW; Cox HM
    Endocrinology; 2018 Apr; 159(4):1704-1717. PubMed ID: 29471473
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DS-8500a, an Orally Available G Protein-Coupled Receptor 119 Agonist, Upregulates Glucagon-Like Peptide-1 and Enhances Glucose-Dependent Insulin Secretion and Improves Glucose Homeostasis in Type 2 Diabetic Rats.
    Matsumoto K; Yoshitomi T; Ishimoto Y; Tanaka N; Takahashi K; Watanabe A; Chiba K
    J Pharmacol Exp Ther; 2018 Dec; 367(3):509-517. PubMed ID: 30217957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [GPR119 Receptor Agonists: Characteristics, Physiological Role, Prospects of Use in the Treatment of Diabetes Mellitus Type 2 and Metabolic Syndrome].
    Tyurenkov IN; Kurkin DV; Bakulin DA; Lomkina EM; Volotova EV
    Usp Fiziol Nauk; 2015; 46(4):28-37. PubMed ID: 27183782
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angelica dahurica Extracts Improve Glucose Tolerance through the Activation of GPR119.
    Park EY; Kim EH; Kim CY; Kim MH; Choung JS; Oh YS; Moon HS; Jun HS
    PLoS One; 2016; 11(7):e0158796. PubMed ID: 27391814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
    Coskun T; Sloop KW; Loghin C; Alsina-Fernandez J; Urva S; Bokvist KB; Cui X; Briere DA; Cabrera O; Roell WC; Kuchibhotla U; Moyers JS; Benson CT; Gimeno RE; D'Alessio DA; Haupt A
    Mol Metab; 2018 Dec; 18():3-14. PubMed ID: 30473097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor.
    Al-Zamel N; Al-Sabah S; Luqmani Y; Adi L; Chacko S; Schneider TD; Krasel C
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31330984
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oleoyl-lysophosphatidylinositol enhances glucagon-like peptide-1 secretion from enteroendocrine L-cells through GPR119.
    Arifin SA; Paternoster S; Carlessi R; Casari I; Ekberg JH; Maffucci T; Newsholme P; Rosenkilde MM; Falasca M
    Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Sep; 1863(9):1132-1141. PubMed ID: 29883799
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lipid derivatives activate GPR119 and trigger GLP-1 secretion in primary murine L-cells.
    Hodge D; Glass LL; Diakogiannaki E; Pais R; Lenaghan C; Smith DM; Wedin M; Bohlooly-Y M; Gribble FM; Reimann F
    Peptides; 2016 Mar; 77():16-20. PubMed ID: 26144594
    [TBL] [Abstract][Full Text] [Related]  

  • 39. GPR119 agonists for type 2 diabetes: past failures and future hopes for preclinical and early phase candidates.
    Hryciw DH; Patten RK; Rodgers RJ; Proietto J; Hutchinson DS; McAinch AJ
    Expert Opin Investig Drugs; 2024 Mar; 33(3):183-190. PubMed ID: 38372052
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endogenous and synthetic agonists of GPR119 differ in signalling pathways and their effects on insulin secretion in MIN6c4 insulinoma cells.
    Ning Y; O'Neill K; Lan H; Pang L; Shan LX; Hawes BE; Hedrick JA
    Br J Pharmacol; 2008 Dec; 155(7):1056-65. PubMed ID: 18724386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.